Noninvasive Prenatal Screening

Noninvasive prenatal screening (NIPS/NIPT) tests can screen for trisomy 21 (Down syndrome) and other chromosomal abnormalities—as well as the sex of your baby—as early as nine weeks into your pregnancy, and with a high degree of accuracy.

Labcorp offers flexibility across our NIPS (NIPT) screening options, talk to your doctor about which option may be right for you

MaterniT® 21 PLUS, the pioneering NIPS (NIPT), screens for common trisomies (such as trisomy 21, Down syndrome), and can be customized to screen for more conditions (eg, DiGeorge syndrome).

GENOME-Flex, a new NIPS (NIPT) high risk pathway. Rapidly re-sequence previously run MaterniT 21 PLUS samples using MaterniT GENOME when late stage anomalies are suspected. Now you have options if a second NIPS (NIPT) is required.

MaterniT® GENOME reports on every chromosome to tell you even more about your baby’s health—our most robust NIPS (NIPT) offering.

Understanding Your MaterniT Results

This video explains what your MaterniT results mean and what next steps or other testing you might consider.

Understanding the difference

NIPS (NIPT) vs. Serum Screening vs. Diagnostic Tests

You may choose to have NIPS (NIPT), a serum screening test, a diagnostic test, a combination of the tests, or no testing at all. Here are the most important differences between the tests:

NIPS (NIPT)

Serum Screening

NOTE: The American College of Obstetricians and Gynecologists recommends that women with a “high risk” maternal serum screening result be offered diagnostic testing. 1 Women with a “low risk” result often choose not to have diagnostic testing.

Diagnostic Tests

NOTE: Not even diagnostic testing can show all birth defects or genetic diseases. No test is perfect: even when all the results of diagnostic testing are normal, all pregnancies still have approximately a 3-5% risk of birth defects.